1. A luliconazole crystal represented by the following formula in which the crystal has a crystal habit such that the (021) plane is its characteristic crystal growth plane: (luliconazole) .2. The crystal according to claim 1, wherein I with respect to the total sum of I, I, I, I, I, I, I, I, I, I, I, II, I and I is not less than 1/3, provided that with respect to diffraction peaks detected in the range 2θ = 5-35 ° in powder x-ray diffractometry using CuKα radiation, the integrated intensities of diffraction peaks that correspond to (001), (100), (10-1), (011), ( 110), (11-1), (10-2), (11 -2), (020), (021), (20-2), (121), (013), (11-3) and ( 221) to the planes designated as I, I, I, I, I, I, I, I, I, I, I, II, I, and I, respectively. 3. A crystal according to claim 1 or 2, wherein the crystal has a monoclinic crystalline system. A crystal according to claim 1 or 2, wherein the crystal is recrystallized from alcohol, which may contain water. A crystal obtained by recrystallization of luliconazole from alcohol, which may contain water. 6. A luliconazole crystal having such a crystalline habit that the chlorine atom and nitrogen atom are located on the characteristic plane of crystal growth. 7. An active pharmaceutical ingredient containing a crystal, as defined in any one of claims. 1-6.8. A method for producing a pharmaceutical composition comprising a step of dissolving in a crystal solvent, as defined in any one of claims. 1-6, or an active pharmaceutical ingredient, as defined in clause 7.9. A pharmaceutical composition obtained by a production method as defined in paragraph 8.1. Кристалл луликоназола, представленный следующей формулой, в котором кристалл обладает таким кристаллическим габитусом, что (021) плоскость является его характеристической плоскостью роста кристалла:(луликоназол).2. Кристалл по п. 1, в котором Iпо отношению к общей сумме I, I, I, I, I, I,I, I, I, I, I, II, Iи Iне меньше, чем 1/3, при условии, что по отношению к дифракционным пикам, обнаруж
